Vimarsana
Biggest News Aggregation in the World

Real Time Cell Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Real Time Cell Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Real Time Cell Analysis Today - Breaking & Trending Today

Agilent Wins Two Scientists' Choice Awards for Drug Discovery and Development Products -February 08, 2024 at 08:07 am EST - Vimarsana News

Agilent Wins Two Scientists' Choice Awards for Drug Discovery and Development Products -February 08, 2024 at 08:07 am EST

Agilent Technologies Inc. announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development...

SLAS2024: Drug Discovery & Development winners announced - Vimarsana News

SLAS2024: Drug Discovery & Development winners announced

Meet the winners of the 2024 Drug Discovery & Development Scientists' Choice Awards which were announced at SLAS 2024

Cancer immunotherapy: Agilent xCELLigence RTCA handbook - Vimarsana News

Cancer immunotherapy: Agilent xCELLigence RTCA handbook

Agilent provides insights into Cancer Immunotherapy and introduces xCELLigence real-time cell analysis

Agilent announces launch of software package for analysing real-time cell analysis data - Vimarsana News

Agilent announces launch of software package for analysing real-time cell analysis data

Reinforces Agilent as a leading cell analysis solutions provider to the pharma and biopharma industries

Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements - Vimarsana News

Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements

Agilent Technologies Inc. today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis... | June 6, 2023